{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:32:59Z","timestamp":1791919979866,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Teaching Reform Research Project of Medical Department of Wuhan University","award":["2019037"],"award-info":[{"award-number":["2019037"]}]},{"name":"Guide Foundation of Renmin Hospital of Wuhan University","award":["RMYD2018M78"],"award-info":[{"award-number":["RMYD2018M78"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00280-020-04195-w","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T13:02:32Z","timestamp":1604754152000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Galeterone sensitizes breast cancer to chemotherapy via targeting MNK\/eIF4E and \u03b2-catenin"],"prefix":"10.1007","volume":"87","author":[{"given":"Yulin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8710-7913","authenticated-orcid":false,"given":"Shan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"issue":"10","key":"4195_CR1","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.7314\/APJCP.2015.16.10.4237","volume":"16","author":"AK Dubey","year":"2015","unstructured":"Dubey AK, Gupta U, Jain S (2015) Breast cancer statistics and prediction methodology: a systematic review and analysis. Asian Pac J Cancer Prev 16(10):4237\u20134245","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"4195_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.24875\/ric.17002175","volume":"69","author":"D Ribnikar","year":"2017","unstructured":"Ribnikar D, Ratosa I, Perhavec A, Amir E (2017) General overview and treatment recommendations for young women with breast cancer. Rev Invest Clin 69(2):77\u201393. https:\/\/doi.org\/10.24875\/ric.17002175","journal-title":"Rev Invest Clin"},{"issue":"20","key":"4195_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"issue":"11","key":"4195_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"4195_CR5","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.1158\/0008-5472.CAN-07-0752","volume":"67","author":"O Larsson","year":"2007","unstructured":"Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K, Bitterman PB, Polunovsky VA (2007) Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res 67(14):6814\u20136824. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0752","journal-title":"Cancer Res"},{"issue":"4","key":"4195_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd4505","volume":"14","author":"M Bhat","year":"2015","unstructured":"Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I (2015) Targeting the translation machinery in cancer. Nat Rev Drug Discov 14(4):261\u2013278. https:\/\/doi.org\/10.1038\/nrd4505","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4195_CR7","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1371\/journal.pone.0000242","volume":"2","author":"Y Mamane","year":"2007","unstructured":"Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK, Sonenberg N (2007) Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE 2(2):e242. https:\/\/doi.org\/10.1371\/journal.pone.0000242","journal-title":"PLoS ONE"},{"issue":"18","key":"4195_CR8","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1182\/blood-2013-01-477216","volume":"121","author":"JK Altman","year":"2013","unstructured":"Altman JK, Szilard A, Konicek BW, Iversen PW, Kroczynska B, Glaser H, Sassano A, Vakana E, Graff JR, Platanias LC (2013) Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. Blood 121(18):3675\u20133681. https:\/\/doi.org\/10.1182\/blood-2013-01-477216","journal-title":"Blood"},{"issue":"2","key":"4195_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18632\/oncotarget.453","volume":"3","author":"J Hou","year":"2012","unstructured":"Hou J, Lam F, Proud C, Wang S (2012) Targeting Mnks for cancer therapy. Oncotarget 3(2):118\u2013131. https:\/\/doi.org\/10.18632\/oncotarget.453","journal-title":"Oncotarget"},{"issue":"15","key":"4195_CR10","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.1128\/MCB.24.15.6539-6549.2004","volume":"24","author":"T Ueda","year":"2004","unstructured":"Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24(15):6539\u20136549. https:\/\/doi.org\/10.1128\/MCB.24.15.6539-6549.2004","journal-title":"Mol Cell Biol"},{"issue":"2","key":"4195_CR11","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.18632\/oncotarget.13772","volume":"8","author":"Z Li","year":"2017","unstructured":"Li Z, Sun Y, Qu M, Wan H, Cai F, Zhang P (2017) Inhibiting the MNK-eIF4E-beta-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy. Oncotarget 8(2):2906\u20132915. https:\/\/doi.org\/10.18632\/oncotarget.13772","journal-title":"Oncotarget"},{"issue":"2","key":"4195_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.18632\/oncotarget.1528","volume":"5","author":"S Ramalingam","year":"2014","unstructured":"Ramalingam S, Gediya L, Kwegyir-Afful AK, Ramamurthy VP, Purushottamachar P, Mbatia H, Njar VC (2014) First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget 5(2):530\u2013543. https:\/\/doi.org\/10.18632\/oncotarget.1528","journal-title":"Oncotarget"},{"issue":"7","key":"4195_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4161\/cbt.10.7.12965","volume":"10","author":"MJ Wheater","year":"2010","unstructured":"Wheater MJ, Johnson PW, Blaydes JP (2010) The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival. Cancer Biol Ther 10(7):728\u2013735. https:\/\/doi.org\/10.4161\/cbt.10.7.12965","journal-title":"Cancer Biol Ther"},{"issue":"25","key":"4195_CR14","doi-asserted-by":"publisher","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","volume":"110","author":"S Lim","year":"2013","unstructured":"Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, Tan SY, Fan H, Chuah CT, Ong ST (2013) Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci USA 110(25):E2298-2307. https:\/\/doi.org\/10.1073\/pnas.1301838110","journal-title":"Proc Natl Acad Sci USA"},{"key":"4195_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.04.004","author":"N Mukherjee","year":"2020","unstructured":"Mukherjee N, Panda CK (2020) Wnt\/beta-catenin signaling pathway as chemotherapeutic target in breast cancer: an update on pros and cons. Clin Breast Cancer. https:\/\/doi.org\/10.1016\/j.clbc.2020.04.004","journal-title":"Clin Breast Cancer"},{"key":"4195_CR16","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2147\/DDDT.S93941","volume":"10","author":"DA Bastos","year":"2016","unstructured":"Bastos DA, Antonarakis ES (2016) Galeterone for the treatment of advanced prostate cancer: the evidence to date. Drug Des Dev Ther 10:2289\u20132297. https:\/\/doi.org\/10.2147\/DDDT.S93941","journal-title":"Drug Des Dev Ther"},{"issue":"21","key":"4195_CR17","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1111\/febs.13895","volume":"283","author":"AK Kwegyir-Afful","year":"2016","unstructured":"Kwegyir-Afful AK, Bruno RD, Purushottamachar P, Murigi FN, Njar VC (2016) Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion. FEBS J 283(21):3898\u20133918. https:\/\/doi.org\/10.1111\/febs.13895","journal-title":"FEBS J"},{"issue":"32","key":"4195_CR18","doi-asserted-by":"publisher","first-page":"52381","DOI":"10.18632\/oncotarget.14154","volume":"8","author":"AK Kwegyir-Afful","year":"2017","unstructured":"Kwegyir-Afful AK, Murigi FN, Purushottamachar P, Ramamurthy VP, Martin MS, Njar VCO (2017) Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget 8(32):52381\u201352402. https:\/\/doi.org\/10.18632\/oncotarget.14154","journal-title":"Oncotarget"},{"issue":"11","key":"4195_CR19","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1182\/blood-2003-07-2193","volume":"103","author":"MG Kharas","year":"2004","unstructured":"Kharas MG, Deane JA, Wong S, O\u2019Bosky KR, Rosenberg N, Witte ON, Fruman DA (2004) Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103(11):4268\u20134275. https:\/\/doi.org\/10.1182\/blood-2003-07-2193","journal-title":"Blood"},{"issue":"2","key":"4195_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"},{"issue":"11","key":"4195_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nchembio.453nchembio.453","volume":"6","author":"CA Thorne","year":"2010","unstructured":"Thorne CA, Hanson AJ, Schneider J, Tahinci E, Orton D, Cselenyi CS, Jernigan KK, Meyers KC, Hang BI, Waterson AG, Kim K, Melancon B, Ghidu VP, Sulikowski GA, LaFleur B, Salic A, Lee LA, Miller DM 3rd, Lee E (2010) Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 6(11):829\u2013836. https:\/\/doi.org\/10.1038\/nchembio.453nchembio.453","journal-title":"Nat Chem Biol"},{"issue":"19","key":"4195_CR22","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869\u201310874. https:\/\/doi.org\/10.1073\/pnas.191367098","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"4195_CR23","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.7150\/jca.18457","volume":"8","author":"X Dai","year":"2017","unstructured":"Dai X, Cheng H, Bai Z, Li J (2017) Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer 8(16):3131\u20133141. https:\/\/doi.org\/10.7150\/jca.18457","journal-title":"J Cancer"},{"issue":"48","key":"4195_CR24","doi-asserted-by":"publisher","first-page":"17406","DOI":"10.1073\/pnas.0505259102","volume":"102","author":"P Clement-Lacroix","year":"2005","unstructured":"Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, Estrera K, Warman ML, Baron R, Rawadi G (2005) Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 102(48):17406\u201317411. https:\/\/doi.org\/10.1073\/pnas.0505259102","journal-title":"Proc Natl Acad Sci USA"},{"key":"4195_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2016.06.005","author":"M Grzmil","year":"2016","unstructured":"Grzmil M, Seebacher J, Hess D, Behe M, Schibli R, Moncayo G, Frank S, Hemmings BA (2016) Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. Cell Signal. https:\/\/doi.org\/10.1016\/j.cellsig.2016.06.005","journal-title":"Cell Signal"},{"issue":"10","key":"4195_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.tibs.2016.07.008","volume":"41","author":"CR Bramham","year":"2016","unstructured":"Bramham CR, Jensen KB, Proud CG (2016) Tuning specific translation in cancer metastasis and synaptic memory: control at the MNK-eIF4E axis. Trends Biochem Sci 41(10):847\u2013858. https:\/\/doi.org\/10.1016\/j.tibs.2016.07.008","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"4195_CR27","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1021\/jm970568r","volume":"41","author":"VC Njar","year":"1998","unstructured":"Njar VC, Kato K, Nnane IP, Grigoryev DN, Long BJ, Brodie AM (1998) Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. J Med Chem 41(6):902\u2013912. https:\/\/doi.org\/10.1021\/jm970568r","journal-title":"J Med Chem"},{"issue":"6","key":"4195_CR28","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1074\/jbc.M111.261933","volume":"287","author":"HS Soifer","year":"2012","unstructured":"Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA (2012) Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 287(6):3777\u20133787. https:\/\/doi.org\/10.1074\/jbc.M111.261933","journal-title":"J Biol Chem"},{"issue":"15","key":"4195_CR29","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1158\/1078-0432.CCR-14-0292","volume":"20","author":"Z Yu","year":"2014","unstructured":"Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP (2014) Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res 20(15):4075\u20134085. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0292","journal-title":"Clin Cancer Res"},{"key":"4195_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fendo.2018.00492","volume":"9","author":"P Giovannelli","year":"2018","unstructured":"Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A (2018) The androgen receptor in breast cancer. Front Endocrinol 9:492. https:\/\/doi.org\/10.3389\/fendo.2018.00492","journal-title":"Front Endocrinol"},{"issue":"22","key":"4195_CR31","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1101\/gad.305631.117","volume":"31","author":"PA Geter","year":"2017","unstructured":"Geter PA, Ernlund AW, Bakogianni S, Alard A, Arju R, Giashuddin S, Gadi A, Bromberg J, Schneider RJ (2017) Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming. Genes Dev 31(22):2235\u20132249. https:\/\/doi.org\/10.1101\/gad.305631.117","journal-title":"Genes Dev"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-020-04195-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04195-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T06:19:21Z","timestamp":1610345961000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-020-04195-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4195"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04195-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,7]]},"assertion":[{"value":"14 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}